Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F17%3A50013391" target="_blank" >RIV/62690094:18470/17:50013391 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/17:10361507
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0014480017300059?via%3Dihub" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0014480017300059?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.yexmp.2017.03.005" target="_blank" >10.1016/j.yexmp.2017.03.005</a>
Alternative languages
Result language
angličtina
Original language name
Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats
Original language description
Doxorubicin (DOX), commonly used antineoplastic agent, affects bone marrow, intestinal tract and heart, but it also has some hepatotoxic effects. Main mechanism of its toxicity is the production of free reactive oxygen species. Polyhidroxilated C-60 fullerene derivatives, fullerenol nanoparticles (FNP), act as free radical scavengers in in vitro systems. The aim of the study was to investigate potential FNP protective role against DOX-induced hepatotoxicity in rats. Experiments were performed on adult male Wistar rats. Animals were divided into five groups: (1) 0.9% NaCl (control), (2) 100 mg/kg ip FNP, (3) 10 mg/kg DOX iv, (4) 50 mg/kg ip FNP 30 min before 10mg/kg ivDOX, (5) 100mg/kg ip FNP 30min before 10mg/kg ivDOX. A general health condition, body and liver weight, TBARS level and antioxidative enzyme activity, as well as pathohistological examination of the liver tissue were conducted on days 2 and 14 of the study. FNP, applied alone, did not alter any examinated parameters. However, when used as a pretreatment it significantly increased survival rate, body and liver weight, and decreased TBARS level, antioxidative enzyme activity and hepatic damage score in DOX-treated rats. FNP administered at a dose of 100mg/kg significantly attenuated effects of doxorubicin administered in a single high dose in rats, concerning general condition, body and liver weight, lipid peroxidation level and antioxidative enzyme activity as well as structural alterations of the hepatic tissue.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Experimental and molecular pathology
ISSN
0014-4800
e-ISSN
—
Volume of the periodical
102
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
360-369
UT code for WoS article
000403040200028
EID of the result in the Scopus database
—